Background Background The highly recurrent
The highly recurrent nature of major depression in the young nature of major depression in the young and the elderly warrants long-term and the elderly warrants long-term antidepressanttreatment. antidepressanttreatment.
Aims Aims To compare the prophylactic
To compare the prophylactic efficacy of citalopram and placebo in efficacy of citalopram and placebo in elderly patients; to evaluate long-term elderly patients; to evaluate long-term tolerability of citalopram. tolerability of citalopram.
Method
Method Out-patients, Out-patients, 5 565 years, 65 years, with unipolar major depression (DSM^IV: with unipolar major depression (DSM^IV: 296.2 296.26 6 or 296.3 or 296.36 6) and Montgomery) and Montgomerysberg Depression Rating Scale score -sberg Depression Rating Scale score 5 522 were treated with citalopram 2022
were treated with citalopram 204 0 mg for 8 weeks.Responders continued 40 mg for 8 weeks.Responders continued on their final fixed dose of citalopram for on their final fixed dose of citalopram for 16 weeks before randomisation to double-16 weeks before randomisationto doubleblind treatment with citalopram or blind treatment with citalopram or placebo for at least 48 weeks. placebo for at least 48 weeks.
Results

Results Nineteen ofthe 60 patients
Nineteen ofthe 60 patients using citalopram using citalopram v.
v. 41of the 61patients 41of the 61patients using placebo had recurrence.Time to using placebo had recurrence.Time to recurrence was significantly different recurrence was significantly different between citalopram-and placebobetween citalopram-and placebopatients, in favour of citalopram (log-rank patients, in favour of citalopram (log-rank test, test, P P5 50.0001).Long-term treatment 0.0001).Long-term treatment was well tolerated. was well tolerated.
Conclusions Conclusions Long-term treatment
Long-term treatment with citalopram is effective in preventing with citalopram is effective in preventing recurrence of depressioninthe elderly and recurrence of depressioninthe elderly and is well tolerated. is well tolerated.
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Depression is common in the elderly; Depression is common in the elderly; 10-15% of elderly persons living in the 10-15% of elderly persons living in the community manifest clinically relevant community manifest clinically relevant symptoms of depression and 1-2% have symptoms of depression and 1-2% have major depression (Beekman major depression (Beekman et al et al, 1999) . , 1999). As in younger adults, the course of depresAs in younger adults, the course of depression in the elderly shows a high degree of sion in the elderly shows a high degree of relapse and/or recurrence (Flint & Rifat, relapse and/or recurrence (Flint & Rifat, 1999) resulting in a conceptualisation of 1999) resulting in a conceptualisation of three phases of antidepressant treatment: three phases of antidepressant treatment: acute treatment (resolution of acute depresacute treatment (resolution of acute depressive symptoms); continuation treatment (4-sive symptoms); continuation treatment (4-6 months relapse prevention); and main-6 months relapse prevention); and maintenance treatment (recurrence prevention, tenance treatment (recurrence prevention, prophylaxis) (Montgomery prophylaxis) (Montgomery et al et al, 1988 (Montgomery et al et al, ). , 1988 . Only a few placebo-controlled studies Only a few placebo-controlled studies have investigated the effect of maintenance have investigated the effect of maintenance treatment in the elderly; not all have treatment in the elderly; not all have followed the scheme outlined above. Howfollowed the scheme outlined above. However, the reported studies have shown a ever, the reported studies have shown a beneficial effect of prophylactic treatment beneficial effect of prophylactic treatment (Georgotas (Georgotas et al et al, 1989; Reynolds , 1989; Reynolds et al et al, , 1999) . This study investigated the efficacy 1999). This study investigated the efficacy of citalopram in recurrence prevention in of citalopram in recurrence prevention in elderly patients with major depression, elderly patients with major depression, using the three-phase scheme outlined using the three-phase scheme outlined above. above.
METHOD METHOD
This was a single-centre study in outThis was a single-centre study in outpatients at the Psychiatric Research Clinic, patients at the Psychiatric Research Clinic, Frederiksberg Hospital. The study conFrederiksberg Hospital. The study consisted of an open-label phase (Periods I-II, sisted of an open-label phase (Periods I-II, acute and continuation treatment periods) acute and continuation treatment periods) and a double-blind, randomised, paralleland a double-blind, randomised, parallelgroup comparison of citalopram (20, 30, group comparison of citalopram (20, 30, or 40 mg/day) and placebo treatment in or 40 mg/day) and placebo treatment in the prevention of depression recurrence the prevention of depression recurrence (Period III). The study was conducted (Period III). The study was conducted according to the Helsinki Declaration according to the Helsinki Declaration (Tokyo, Venice, Hong Kong and Somerset (Tokyo, Venice, Hong Kong and Somerset West, amendments 1975 , 1983 , 1989 and West, amendments 1975 , 1983 , 1989 and 1996 565 years aimed at identi-65 years aimed at identifying undiscovered depression in that popufying undiscovered depression in that population. Those who were found to be lation. Those who were found to be depressed and fulfilled the entry criteria depressed and fulfilled the entry criteria for the screening procedure at the research for the screening procedure at the research clinic were eligible for the study. All clinic were eligible for the study. All patients gave written informed consent patients gave written informed consent before being included in the study. before being included in the study.
Patients included had a unipolar Patients included had a unipolar major depressive episode (MDE; DSM-IV: major depressive episode (MDE; DSM-IV: 296.2 296.26 6 or 296.3 or 296.36 6; American Psychiatric ; American Psychiatric Association, 1993) at a severity corresAssociation, 1993) at a severity corresponding to a total score of ponding to a total score of 5 522 on the 22 on the Montgomery-Asberg Depression Rating Montgomery-Å sberg Depression Rating Scale (MADRS; Montgomery & Asberg, Scale (MADRS; Montgomery & Å sberg, 1979) . 1979).
Patients were excluded from the study if Patients were excluded from the study if the index episode had lasted more than 12 the index episode had lasted more than 12 months; if they had a history of schizomonths; if they had a history of schizophrenia, mania, hypomania, epilepsy, drug phrenia, mania, hypomania, epilepsy, drug or alcohol misuse; or if they had severe or alcohol misuse; or if they had severe somatic disorders. Similarly, patients were somatic disorders. Similarly, patients were excluded if they had received fluoxetine excluded if they had received fluoxetine within 5 weeks or other antidepressants within 5 weeks or other antidepressants within 3 days of the start of the study, within 3 days of the start of the study, lithium, carbamazepine or valproate within lithium, carbamazepine or valproate within 2 weeks of the study, electroconvulsive 2 weeks of the study, electroconvulsive therapy within 8 weeks of the study or therapy within 8 weeks of the study or sumatriptan or anticoagulants at study sumatriptan or anticoagulants at study start. Finally, patients were excluded if they start. Finally, patients were excluded if they had a score of had a score of 5 55 on MADRS item 10 5 on MADRS item 10 (suicidality). (suicidality).
Study design Study design
The study consisted of three periods: Period The study consisted of three periods: (June, 1999) . discontinued for any reason (June, 1999) .
In Period I, the initial dose of citaloIn Period I, the initial dose of citalopram was 10 mg/day for the first 3 days, pram was 10 mg/day for the first 3 days, then increased to 20 mg/day. After 1 week, then increased to 20 mg/day. After 1 week, the dose could be decreased to 10 mg/day in the dose could be decreased to 10 mg/day in 2 9 2 9 
Visits and assessments Visits and assessments
In Period I, patients were seen for a screenIn Period I, patients were seen for a screening and a baseline visit, and also at weeks 1, ing and a baseline visit, and also at weeks 1, 3, 5 and 8. In Period II, patients were seen 3, 5 and 8. In Period II, patients were seen upon entry ( upon entry (¼last visit in Period I), and at last visit in Period I), and at weeks 4, 8, 12 and 16. In Period III, weeks 4, 8, 12 and 16 . In Period III, patients were seen at entry ( patients were seen at entry (¼last visit in last visit in Period II) and at weeks 2 and 4, and subsePeriod II) and at weeks 2 and 4, and subsequently every 4 weeks until discontinuation quently every 4 weeks until discontinuation or completion. In addition, all patients or completion. In addition, all patients were seen for a discontinuation or complewere seen for a discontinuation or completion visit. tion visit.
Patients were assessed by the CGI-S, Patients were assessed by the CGI-S, MADRS, the 17-item Hamilton Depression MADRS, the 17-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1960), and Rating Scale (HDRS; Hamilton, 1960) , and the Melancholia Scale (MES; Bech the Melancholia Scale (MES; Bech et al et al, , 1986) at baseline, at all subsequent visits 1986) at baseline, at all subsequent visits in all periods (except for the visit at week in all periods (except for the visit at week 1 in Period I) and at premature discon-1 in Period I) and at premature discontinuations. Concomitant medication and tinuations. Concomitant medication and adverse events were noted at each visit. adverse events were noted at each visit. Patient history and physical examination Patient history and physical examination were registered at baseline. Laboratory tests were registered at baseline. Laboratory tests were performed at the screening visit in were performed at the screening visit in Period I, at entry into Period III and at Period I, at entry into Period III and at discontinuation/completion. Vital signs discontinuation/completion. Vital signs were assessed at entry into Period I, at week were assessed at entry into Period I, at week 8, at completion of Period II and at the end 8, at completion of Period II and at the end of each 24-week period in Period III. of each 24-week period in Period III. Height and body weight were recorded at Height and body weight were recorded at baseline. baseline.
Outcome measures and definitions Outcome measures and definitions
The primary measure of prophylactic The primary measure of prophylactic efficacy was the time to recurrence of a efficacy was the time to recurrence of a depressive episode from the start of Period depressive episode from the start of Period III. Recurrence of depression was defined III. Recurrence of depression was defined as the patient reaching a MADRS total as the patient reaching a MADRS total score of score of 5 522, confirmed after 3-7 days. 22, confirmed after 3-7 days. The assessment of safety and tolerThe assessment of safety and tolerability of citalopram during prophylactic ability of citalopram during prophylactic treatment was based on reporting of treatment was based on reporting of adverse events, vital sign measurements adverse events, vital sign measurements and laboratory assessments. Adverse events and laboratory assessments. Adverse events were either reported spontaneously by the were either reported spontaneously by the patient, observed by the investigator, or patient, observed by the investigator, or elicited by the investigator using open elicited by the investigator using open questioning. questioning.
Statistical analysis Statistical analysis
In the primary analysis, the log-rank test In the primary analysis, the log-rank test was used to compare the time to recurrence was used to compare the time to recurrence of depression for patients treated with of depression for patients treated with citalopram or placebo. Survival curves were citalopram or placebo. Survival curves were estimated using the Kaplan-Meier method estimated using the Kaplan-Meier method and overall treatment effect was estimated and overall treatment effect was estimated using the Cox proportional hazard model using the Cox proportional hazard model (Andersen (Andersen et al et al, 1993; SAS Institute Inc., , 1993 ; SAS Institute Inc., 1997). 1997).
In order to have a power of at least In order to have a power of at least 90% at a 5% significance level for the 90% at a 5% significance level for the primary analysis, a minimum sample size primary analysis, a minimum sample size of 150 patients randomised into Period of 150 patients randomised into Period III III (75 patients/group) was estimated (75 patients/group) was estimated (Goldman & Hillman, 1992) . This was (Goldman & Hillman, 1992) . This was calculated to require inclusion of approxicalculated to require inclusion of approximately 300 patients. The actual number of mately 300 patients. The actual number of patients included in the study was 230. patients included in the study was 230.
The power at a 5% significance level was The power at a 5% significance level was re-estimated to be 60-75%. re-estimated to be 60-75%.
RESULTS RESULTS
Disposition of patients Disposition of patients
A total of 230 patients entered Period I A total of 230 patients entered Period I (acute treatment; Fig. 1 ), of whom 172 (acute treatment; Fig. 1 The primary reasons for discontinuaThe primary reasons for discontinuation in Period I were adverse events (13%) tion in Period I were adverse events (13%) and withdrawal of consent (10%), whereas and withdrawal of consent (10%), whereas in Period II the main reasons were within Period II the main reasons were withdrawal of consent (15%), lack of efficacy drawal of consent (15%), lack of efficacy (8%) and adverse events (5%). (8%) and adverse events (5%).
All patients randomised into Period III All patients randomised into Period III were included in the intention-to-treat were included in the intention-to-treat (ITT) population for analysis of efficacy.
(ITT) population for analysis of efficacy. This population comprised 23% males This population comprised 23% males and 77% females, which is a good and 77% females, which is a good representation of a population of elderly representation of a population of elderly patients with depression (Brown patients with depression (Brown et al et al, , 1995) . 1995).
Demographics and baseline Demographics and baseline characteristics of patients characteristics of patients
Demographics and baseline characteristics Demographics and baseline characteristics of the patients were similar for the two of the patients were similar for the two treatment groups (Table 1) . A total of treatment groups (Table 1) . A total of 15% of the randomised patients in both 15% of the randomised patients in both groups had a history of previously diaggroups had a history of previously diagnosed MDEs, of whom none reported nosed MDEs, of whom none reported having had more than two. In both treathaving had more than two. In both treatment groups, the great majority of patients ment groups, the great majority of patients were 'moderately ill' or 'markedly ill' at were 'moderately ill' or 'markedly ill' at baseline (CGI-S ratings), with about half baseline (CGI-S ratings), with about half the patients in each of these categories. the patients in each of these categories. Approximately 18% of the patients in both Approximately 18% of the patients in both groups had previously received pharmacogroups had previously received pharmacological treatment for depression (except logical treatment for depression (except one citalopram patient who had had one citalopram patient who had had electroconvulsive therapy). However, none electroconvulsive therapy). However, none of the patients had been treated with of the patients had been treated with psychotropics within the last 3 months. A psychotropics within the last 3 months. A family history of major depression was family history of major depression was noted for 15% (citalopram) and 11.5% noted for 15% (citalopram) and 11.5% (placebo) of the patients, respectively. (placebo) of the patients, respectively.
Concurrent medical conditions and Concurrent medical conditions and medication medication
There was no significant difference between There was no significant difference between treatment groups in respect of concurrent treatment groups in respect of concurrent diseases and concomitant drug therapy. diseases and concomitant drug therapy. Approximately 72% of the patients in both Approximately 72% of the patients in both treatment groups had an ongoing medical treatment groups had an ongoing medical condition at baseline, and about 78% of condition at baseline, and about 78% of the patients in both groups were continuing the patients in both groups were continuing with at least one kind of medication upon with at least one kind of medication upon entry into Period III. entry into Period III.
MADRS, HDRS and MES scores MADRS, HDRS and MES scores
For the ITT population, the baseline total For the ITT population, the baseline total MADRS scores (s.d.) at entry into Periods I MADRS scores (s.d.) at entry into Periods I and III were 27.0 (3.4) and 4.7 (3.7), respectand III were 27.0 (3.4) and 4.7 (3.7), respectively, in the citalopram group and 26.7 (3.1) ively, in the citalopram group and 26.7 (3.1) and 3.9 (3.5), respectively, in the placebo and 3.9 (3.5), respectively, in the placebo group. The total HDRS scores were 17.2 group. The total HDRS scores were 17.2 (2.8) and 3.3 (2.7) (citalopram) and 17.2 (2.8) and 3.3 (2.7) (citalopram) and 17.2 (3.2) and 2.9 (2.6) (placebo), respectively, (3.2) and 2.9 (2.6) (placebo), respectively, and the total MES scores were 16.3 (2.8) and the total MES scores were 16.3 (2.8) and 3.6 (2.8) (citalopram) and 16.7 (2.9) and 3.6 (2.8) (citalopram) and 16.7 (2.9) and 3.0 (2.7) (placebo), respectively. and 3.0 (2.7) (placebo), respectively.
Recurrence of depression in the Recurrence of depression in the double-blind Period III double-blind Period III
In the 60 patients randomised to continue In the 60 patients randomised to continue on citalopram, there were 19 recurrences on citalopram, there were 19 recurrences (32%) in contrast to 41 recurrences in the (32%) in contrast to 41 recurrences in the 61 patients randomised to placebo (67%). 61 patients randomised to placebo (67%). The total observation time from randomisThe total observation time from randomisation into Period III until recurrence, ation into Period III until recurrence, completion or discontinuation for other completion or discontinuation for other reasons than recurrence, was 53.8 (citaloreasons than recurrence, was 53.8 (citalopram) and 30.3 (placebo) person-years, pram) and 30.3 (placebo) person-years, respectively. At week 48, 18 patients in respectively. At week 48, 18 patients in the citalopram group and 38 patients in the citalopram group and 38 patients in the placebo group had experienced a recurthe placebo group had experienced a recurrence of depression ( Table 2 ). The estirence of depression ( Table 2 ). The estimated probability of no recurrence within mated probability of no recurrence within 48 weeks was 0.67 for patients treated with 48 weeks was 0.67 for patients treated with citalopram and 0.27 for placebo-treated citalopram and 0.27 for placebo-treated patients. The time to recurrence in Period patients. The time to recurrence in Period III differed significantly between the treat-III differed significantly between the treatment groups, in favour of citalopram (logment groups, in favour of citalopram (logrank test, rank test, w w v. placebo) was estimated at placebo) was estimated at 0.32 (95% CI 0.19-0.56) using a Cox 0.32 (95% CI 0.19-0.56) using a Cox regression model with treatment as the only regression model with treatment as the only predictive factor. predictive factor.
Although the study was not powered Although the study was not powered for subgroup analysis, and despite the fact for subgroup analysis, and despite the fact that a limited number of patients received that a limited number of patients received 20 mg/day, the difference in time to recur-20 mg/day, the difference in time to recurrence between citalopram-and placeborence between citalopram-and placebotreated patients was statistically significant treated patients was statistically significant 31 31 at all three dose levels (log-rank test, 20 mg/ at all three dose levels (log-rank test, 20 mg/ day, day, P P¼0.0009; 30 mg/day, 0.0009; 30 mg/day, P P¼0.0227; 0.0227; 40 mg/day, 40 mg/day, P P¼0.0188). In the 20 mg/day 0.0188). In the 20 mg/day group, none of the patients continuing on group, none of the patients continuing on citalopram experienced a recurrence citalopram experienced a recurrence whereas all the patients switched to placebo whereas all the patients switched to placebo did. did.
Discontinuation in the double-blind Discontinuation in the double-blind Period III Period III
The majority of discontinuations in Period The majority of discontinuations in Period III occurred in the placebo group (55 III occurred in the placebo group (55 (90%), compared with 37 (62%) in the (90%), compared with 37 (62%) in the citalopram group). The most frequent citalopram group). The most frequent reason was recurrence of depression (citaloreason was recurrence of depression (citalopram 19 (32%); placebo 41 (67%)) pram 19 (32%); placebo 41 (67%)) followed by withdrawal of consent (about followed by withdrawal of consent (about 24% in both groups). A few patients dis-24% in both groups). A few patients discontinued because of adverse events (citalocontinued because of adverse events (citalopram 10%; placebo 13%) with no pram 10%; placebo 13%) with no difference in time to withdrawal between difference in time to withdrawal between the two groups (log-rank test, the two groups (log-rank test, P P¼0.1842). 0.1842).
Safety and tolerability Safety and tolerability
In Period I, the most frequent adverse In Period I, the most frequent adverse events ( events (5 55%) were nausea, diarrhoea, 5%) were nausea, diarrhoea, headache, increased sweating, tremor, headache, increased sweating, tremor, dizziness and fatigue (Table 3) . Similar dizziness and fatigue (Table 3) . Similar symptoms, but with a reduced frequency, symptoms, but with a reduced frequency, were seen in Period II. Sexual side-effects were seen in Period II. Sexual side-effects (spontaneous reporting) were rare and (spontaneous reporting) were rare and weight gain/loss was reported by only two weight gain/loss was reported by only two patients. patients.
Although data should be interpreted Although data should be interpreted with caution, given the low number of with caution, given the low number of events and the longer exposure time (about events and the longer exposure time (about twice as long) for patients treated with twice as long) for patients treated with citalopram than for patients on placebo, citalopram than for patients on placebo, the pattern of adverse events for those the pattern of adverse events for those who continued in Period III was similar in who continued in Period III was similar in the two treatment groups (Table 3 ). The the two treatment groups (Table 3 ). The only events occurring in Period III at a only events occurring in Period III at a frequency frequency 4 45% and at least twice as 5% and at least twice as frequently in the citalopram group as in frequently in the citalopram group as in the placebo group, were back pain and the placebo group, were back pain and influenza-like symptoms. None of these influenza-like symptoms. None of these events were considered to be related to events were considered to be related to treatment. The events most consistently treatment. The events most consistently rated as treatment-related were nausea, rated as treatment-related were nausea, diarrhoea, headache, increased sweating, diarrhoea, headache, increased sweating, tremor, dizziness and fatigue, consistent tremor, dizziness and fatigue, consistent with the known adverse event profile of with the known adverse event profile of citalopram (Noble & Benfield, 1997) . Of citalopram (Noble & Benfield, 1997) . Of these, only increased sweating, tremor and these, only increased sweating, tremor and fatigue were seen fatigue were seen with a statistically highwith a statistically higher frequency in er frequency in the citalopram group comthe citalopram group compared with the placebo group in Period III. pared with the placebo group in Period III.
Changes in laboratory or vital sign Changes in laboratory or vital sign parameters were seen occasionally but were parameters were seen occasionally but were generally all single-parameter changes, generally all single-parameter changes, unlikely to be related to the use of citalounlikely to be related to the use of citalopram. A total of 8 of the 230 patients had pram. A total of 8 of the 230 patients had alanine aminotransferase values out of alanine aminotransferase values out of normal range after baseline. However, normal range after baseline. However, three of these patients already had abnorthree of these patients already had abnormal values at baseline, and all values were mal values at baseline, and all values were only slightly increased. One patient discononly slightly increased. One patient discontinued prematurely because of an increase tinued prematurely because of an increase 3 2 3 2 Table 2  Table 2 Number of patients still under observation, the cumulative number of recurrences and the estimated cumulative proportion of recurrence-free patients (using Number of patients still under observation, the cumulative number of recurrences and the estimated cumulative proportion of recurrence-free patients (using in alanine aminotransferase, which the in alanine aminotransferase, which the investigator considered probably to be investigator considered probably to be related to treatment. The parameter had related to treatment. The parameter had normalised 4 months later. normalised 4 months later. The abrupt discontinuation of citaloThe abrupt discontinuation of citalopram in patients randomised to the placebo pram in patients randomised to the placebo group neither induced new adverse events group neither induced new adverse events nor resulted in an increased intensity of nor resulted in an increased intensity of adverse events present at randomisation. adverse events present at randomisation.
A total of 34 serious adverse events were A total of 34 serious adverse events were reported in 28 patients during the study, of reported in 28 patients during the study, of which 18 were reported during the open which 18 were reported during the open treatment periods and 16 (11 in the citalotreatment periods and 16 (11 in the citalopram group and 5 in the placebo group) pram group and 5 in the placebo group) during the double-blind treatment period. during the double-blind treatment period. There were two serious adverse events with There were two serious adverse events with outcome death: one from oesophageal outcome death: one from oesophageal carcinoma, occurring during the open treatcarcinoma, occurring during the open treatment period; and one for unknown reasons, ment period; and one for unknown reasons, occurring in a placebo patient. Neither of occurring in a placebo patient. Neither of these deaths nor the other serious adverse these deaths nor the other serious adverse events were judged by the investigator to events were judged by the investigator to be related to treatment. be related to treatment.
DISCUSSION DISCUSSION
This study clearly demonstrates the advanThis study clearly demonstrates the advantage of citalopram over placebo in the pretage of citalopram over placebo in the prevention of recurrence of depression in vention of recurrence of depression in elderly patients with unipolar major depreselderly patients with unipolar major depression. It is the first placebo-controlled, sion. It is the first placebo-controlled, double-blind study evaluating the effect of double-blind study evaluating the effect of a selective serotonin reuptake inhibitor a selective serotonin reuptake inhibitor (SSRI) against recurrent depression in (SSRI) against recurrent depression in elderly patients using the generally accepted elderly patients using the generally accepted three-phase prophylactic design (Montthree-phase prophylactic design (Montgomery gomery et al et al, 1988) . The hazard ratio of , 1988). The hazard ratio of recurrence in citalopram-treated patients recurrence in citalopram-treated patients versus those on placebo was estimated at versus those on placebo was estimated at 0.32. Thus, the risk of recurrence was three 0.32. Thus, the risk of recurrence was three times higher for patients on placebo than times higher for patients on placebo than for patients on citalopram. The efficacy of for patients on citalopram. The efficacy of citalopram was seen at all dose levels tested citalopram was seen at all dose levels tested (20, 30 and 40 mg/day). (20, 30 and 40 mg/day).
Comparison with studies
Comparison with studies in 18 -to 65-year-olds in 18 -to 65-year-olds
Essentially similar results were obtained in Essentially similar results were obtained in a recent placebo-controlled citalopram a recent placebo-controlled citalopram study of the same design in 18-to 65-study of the same design in 18-to 65-year-old patients with recurrent depression year-old patients with recurrent depression (Hochstrasser (Hochstrasser et al et al, 2001 ). Reynolds , 2001). Reynolds et al et al (1994) also found that outcomes of main-(1994) also found that outcomes of maintenance therapy were remarkably similar tenance therapy were remarkably similar in elderly and younger patients with depresin elderly and younger patients with depression. Compared with the 18-to 65-yearsion. Compared with the 18-to 65-yearolds (Bougerol olds (Bougerol et al et al, 1997) , elderly patients , 1997), elderly patients tended to need a longer time to respond tended to need a longer time to respond to acute treatment and a shorter time to to acute treatment and a shorter time to recurrence. Both a longer time to remission recurrence. Both a longer time to remission (Reynolds (Reynolds et al et al, 1996) and a higher , 1996) and a higher and and more rapid rate of recurrence with older more rapid rate of recurrence with older age have been reported previously age have been reported previously (Reynolds (Reynolds et al et al, 1999) . , 1999). Only 15% of the randomised elderly Only 15% of the randomised elderly patients in this study had a history of prepatients in this study had a history of previously diagnosed depression. Furthermore, viously diagnosed depression. Furthermore, a family history of depression was about a family history of depression was about half as frequent in this study as in a half as frequent in this study as in a comparable study in 18-to 65-year-olds comparable study in 18-to 65-year-olds (Hochstrasser (Hochstrasser et al et al, 2001 ) consistent with , 2001) consistent with the known profile in late-onset depression the known profile in late-onset depression (Small, 1998) . In spite of the absence of (Small, 1998) . In spite of the absence of these known risk factors for recurrence of these known risk factors for recurrence of depression, the results of the present study depression, the results of the present study demonstrate that the population it included demonstrate that the population it included was at high risk of recurrence. The results was at high risk of recurrence. The results confirm that the risk of recurrence in confirm that the risk of recurrence in geriatric patients is high, even after firstgeriatric patients is high, even after firstepisode depression (Flint & Rifat, 1999; episode depression (Flint & Rifat, 1999; Reynolds Reynolds et al et al, 1999) . , 1999).
Study design Study design
This study was designed to allow sufficient This study was designed to allow sufficient time to resolve symptoms of an episode of time to resolve symptoms of an episode of unipolar major depression and to distinunipolar major depression and to distinguish relapse of an episode from recurrence guish relapse of an episode from recurrence of a new episode (Montgomery of a new episode (Montgomery et al et al, 1988) . , 1988). Period I was designed to optimise response Period I was designed to optimise response to citalopram (flexible dose and treatment to citalopram (flexible dose and treatment extension up to 12 weeks), possibly extension up to 12 weeks), possibly explaining why only 3% of the patients disexplaining why only 3% of the patients discontinued because of lack of efficacy, continued because of lack of efficacy, reflecting the fact that a long time reflecting the fact that a long time for for resolution of symptoms could be reresolution of symptoms could be required in some patients (Quitkin, quired in some patients (Quitkin, 1992) . 1992). Period II was designed to consoliPeriod II was designed to consolidate remission from the present depressive date remission from the present depressive 3 3 3 3 1. Data should be interpreted with caution given the difference in exposure time to double-blind medication, which 1. Data should be interpreted with caution given the difference in exposure time to double-blind medication, which was about twice as long for citalopram patients as for placebo patients. was about twice as long for citalopram patients as for placebo patients. 2. Percentage is relative to the male sub-population. 2. Percentage is relative to the male sub-population.
episode (Montgomery episode (Montgomery et al et al, 1988) . The , 1988) . The following 48-week minimum duration of following 48-week minimum duration of prophylactic therapy was chosen on the prophylactic therapy was chosen on the basis of the current knowledge of the time basis of the current knowledge of the time to recurrence seen in most depressive to recurrence seen in most depressive patients (about 24 weeks), but allowing patients (about 24 weeks), but allowing enough time to obtain knowledge of recurenough time to obtain knowledge of recurrences occurring at later time-points; and rences occurring at later time-points; and of statistical power calculations. of statistical power calculations.
Treatment Treatment
The doses of 20, 30 or 40 mg/day citaloThe doses of 20, 30 or 40 mg/day citalopram were chosen on the basis of previous pram were chosen on the basis of previous 12-week studies of citalopram in elderly 12-week studies of citalopram in elderly patients with depression (Kyle patients with depression (Kyle et al et al, 1998) , 1998) and on the well-established long-term effiand on the well-established long-term efficacy and safety of doses of 20-40 mg/day cacy and safety of doses of 20-40 mg/day citalopram in 18-to 65-year-old patients citalopram in 18-to 65-year-old patients (Robert & Montgomery, 1995) . The dose (Robert & Montgomery, 1995) . The dose to which patients responded during acute to which patients responded during acute treatment, and remained well on during treatment, and remained well on during continuation treatment, was maintained continuation treatment, was maintained during prophylactic treatment, as studies during prophylactic treatment, as studies have indicated that a full dose of antihave indicated that a full dose of antidepressants is more effective than a reduced depressants is more effective than a reduced dose during prophylactic treatment (Frandose during prophylactic treatment (Franchini chini et al et al, 1998). , 1998).
Relapse versus recurrence Relapse versus recurrence
It might be questioned whether the depresIt might be questioned whether the depressive episodes recorded in Period III were sive episodes recorded in Period III were relapses rather than recurrences. However, relapses rather than recurrences. However, because the design of the study followed because the design of the study followed the recommendations given by the experts the recommendations given by the experts in this field (Montgomery in this field (Montgomery et al et al, 1988 (Montgomery et al et al, ), , 1988 , new depressive episodes occurring in Period new depressive episodes occurring in Period III were regarded as recurrences. This is III were regarded as recurrences. This is further substantiated by the fact that the further substantiated by the fact that the duration of an untreated depressive episode duration of an untreated depressive episode is usually considered to be 6-8 months is usually considered to be 6-8 months (American Psychiatric Association, 1993) . (American Psychiatric Association, 1993) . When patients entered Period III in this When patients entered Period III in this study, their index episode had started at study, their index episode had started at least 6.5 months earlier. Furthermore, if least 6.5 months earlier. Furthermore, if the patients, although symptom free, were the patients, although symptom free, were still in the depressive phase of their index still in the depressive phase of their index episode when they entered Period III, it is episode when they entered Period III, it is most likely that the patients randomised most likely that the patients randomised to placebo would relapse very early. Thus, to placebo would relapse very early. Thus, the difference in treatment effect of citalothe difference in treatment effect of citalopram and placebo should be greatest at pram and placebo should be greatest at the time immediately following randomisthe time immediately following randomisation. The fact is, however, that a subation. The fact is, however, that a substantial part of the recurrences occurred in stantial part of the recurrences occurred in weeks 8-12 after randomisation, and citaweeks 8-12 after randomisation, and citalopram was superior to placebo in preventlopram was superior to placebo in preventing recurrence throughout the observation ing recurrence throughout the observation period. period.
Safety and tolerability of Safety and tolerability of prophylactic treatment prophylactic treatment
Prophylactic treatment with citalopram Prophylactic treatment with citalopram was well tolerated in the elderly patients was well tolerated in the elderly patients in this study. This is an important finding, in this study. This is an important finding, given the particular vulnerability of elderly given the particular vulnerability of elderly patients to adverse drug reactions and the patients to adverse drug reactions and the high frequency of concurrent diseases and high frequency of concurrent diseases and concomitant drug therapy in these patients concomitant drug therapy in these patients (Pollock, 1999) . (Pollock, 1999) .
The pattern of adverse events was in The pattern of adverse events was in agreement with other results regarding agreement with other results regarding long-term safety of SSRIs (Zajecka long-term safety of SSRIs (Zajecka et al et al, , 1999) and was comparable to the adverse 1999) and was comparable to the adverse events seen in placebo-treated patients. events seen in placebo-treated patients. Notably, sexual symptoms, a common Notably, sexual symptoms, a common and bothersome reaction to SSRIs (Kennedy and bothersome reaction to SSRIs (Kennedy et al et al, 2000) , were reported with very low , 2000), were reported with very low frequency. However, the frequency could frequency. However, the frequency could have been underestimated because specific have been underestimated because specific enquiries were not made about these enquiries were not made about these events. Weight gain was only reported by events. Weight gain was only reported by one patient (citalopram) in Period III in one patient (citalopram) in Period III in agreement with a previous long-term study agreement with a previous long-term study (Hochstrasser (Hochstrasser et al et al, 2001) . , 2001).
Premature discontinuation Premature discontinuation
Apart from recurrence, the most common Apart from recurrence, the most common primary reasons for premature discontinuaprimary reasons for premature discontinuations in Period III were withdrawal of tions in Period III were withdrawal of consent and adverse events, which is to be consent and adverse events, which is to be expected in a long-term study in an elderly expected in a long-term study in an elderly population. It is of major importance that population. It is of major importance that the abrupt discontinuation of citalopram the abrupt discontinuation of citalopram in patients randomised to the placebo in patients randomised to the placebo group caused no worsening of the adverse group caused no worsening of the adverse event profile. Although the sample size event profile. Although the sample size was small and the study was not designed was small and the study was not designed to investigate this, it indicates that abrupt to investigate this, it indicates that abrupt discontinuation of citalopram in the elderly discontinuation of citalopram in the elderly is not associated with discontinuation is not associated with discontinuation symptoms. symptoms.
In conclusion, citalopram effectively In conclusion, citalopram effectively reduces the rate of recurrence of depression reduces the rate of recurrence of depression The risk of recurrence in a group of elderly patients with depression is three times higher following switch to placebo than following continuation on the active drug. higher following switch to placebo than following continuation on the active drug.
& & Long-term treatment in the elderly (average 75 years of age) is well tolerated.
Long-term treatment in the elderly (average 75 years of age) is well tolerated.
LIMITATIONS LIMITATIONS
& & The study does not permit evaluation of reduced dose effectiveness in The study does not permit evaluation of reduced dose effectiveness in maintenance treatment. maintenance treatment.
& & Because fewer patients were included in the study than originally planned, the Because fewer patients were included in the study than originally planned, the power of the study was decreased. power of the study was decreased. Although conclusive and concordant with data in adults, confirmation of study findings is required as this is the first study of its kind with a selective serotonin findings is required as this is the first study of its kind with a selective serotonin reuptake inhibitor. reuptake inhibitor. in elderly patients. Moreover, long-term in elderly patients. Moreover, long-term treatment with citalopram is well tolerated. treatment with citalopram is well tolerated. This study confirms available data indicatThis study confirms available data indicating that maintenance treatment in patients ing that maintenance treatment in patients with depression is efficacious in reducing with depression is efficacious in reducing recurrence rates and is beneficial even after recurrence rates and is beneficial even after first-episode depression. first-episode depression.
